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Derivation and Characterization of Induced Pluripotent
Stem Cells from Equine Fibroblasts
Amandine Breton,1 Ruchi Sharma,1 Andrea Catalina Diaz,1 Alea Gillian Parham,1 Audrey Graham,2
Claire Neil,1 Christopher Bruce Whitelaw,1 Elspeth Milne,2 and Francesc Xavier Donadeu1
Pluripotent stem cells offer unprecedented potential not only for human medicine but also for veterinary
medicine, particularly in relation to the horse. Induced pluripotent stem cells (iPSCs) are particularly promising,
as they are functionally similar to embryonic stem cells and can be generated in vitro in a patient-specific
manner. In this study, we report the generation of equine iPSCs from skin fibroblasts obtained from a foal and
reprogrammed using viral vectors coding for murine Oct4, Sox2, c-Myc, and Klf4 sequences. The reprogrammed
cell lines were morphologically similar to iPSCs reported from other species and could be stably maintained over
more than 30 passages. Immunostaining and polymerase chain reaction analyses revealed that these cell lines
expressed an array of endogenous markers associated with pluripotency, including OCT4, SOX2, NANOG,
REX1, LIN28, SSEA1, SSEA4, and TRA1-60. Furthermore, under the appropriate conditions, the equine iPSCs
readily formed embryoid bodies and differentiated in vitro into cells expressing markers of ectoderm, meso-
derm, and endoderm, and when injected into immunodeficient mice, gave raise to tumors containing differ-
entiated derivatives of the 3 germ layers. Finally, we also reprogrammed fibroblasts from a 2-year-old horse. The
reprogrammed cells were similar to iPSCs derived from neonatal fibroblasts in terms of morphology, expression
of pluripotency markers, and differentiation ability. The generation of these novel cell lines constitutes an
important step toward the understanding of pluripotency in the horse, and paves the way for iPSC technology to
potentially become a powerful research and clinical tool in veterinary biomedicine.
Introduction
Horses are highly valued as both companion andsporting animals; the horse industry is estimated to be
worth US$300 billion worldwide. Equine health is a major
concern to the horse racing industry with the cost of injuries
and illnesses worldwide being about US$6.5 billion each year
[1]. Musculoskeletal problems are a leading cause of poor
health among race horses. For example, as many as 5% of
competition horses will suffer from tendon or ligament in-
juries during their careers, and only 25%–50% of those will
compete again [2]. Traditional therapeutic options only
provide a short-term solution and are associated with a high
rate of reoccurrence [3]. The therapeutic use of stem cells
provides, in principle, a better alternative to achieve resto-
ration of normal tissue function, and adult bone marrow- or
adipose tissue-derived cells have been used clinically for the
treatment of musculoskeletal injuries in horses during the
last decade with encouraging results [4]. However, several
factors severely limit the efficacy of current adult stem cell
therapies, namely the very low fraction of truly multipotent
precursor cells that can be obtained in vivo (< 0.01%), the
high heterogeneity of such cell populations, and their limited
replication and differentiation potential [5,6]. In this context,
the derivation of pluripotent stem cell lines from horses
may provide a superior alternative, as such cells have the
ability to proliferate indefinitely while maintaining an
undifferentiated state, and have unrestricted differentiation
potential. However, attempts to obtain bona fide embryonic
stem cells (ESCs) from species other than rodents and
humans have been largely unsuccessful [7]. At present,
2 different teams have reported the generation of ES-like
cells from horses [8,9]. The reported cell lines displayed
ESC features, but failed to form teratomas after injection
into mice [9].
A major breakthrough in stem cell biology occurred in
2006 when Takahashi and Yamanaka reported the produc-
tion of pluripotent stem cells in vitro by using retroviruses to
force the expression of 4 transcription factors, Oct4, Sox2,
Klf4, and c-Myc, into adult mouse fibroblasts [10]. Since then,
induced pluripotent stem cells (iPSCs) or iPSC-like cells have
been derived from different species, including human [11],
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rhesus monkey [12], rat [13], pig [14,15], dog [16,17], rabbit
[18], marmoset [19], sheep [20–22], and more recently, horse
[23] and cow [24]. Transgene-mediated reprogramming of-
fers distinct technical advantages over other established re-
programming techniques, and the resulting cell lines are
functionally comparable to ESCs [25]. Moreover, iPSCs can,
in principle, be produced in a patient-specific manner, a
feature that would provide these cells with considerable
potential for regenerative medicine and in vitro disease
modeling. However, full realization of this potential will first
require addressing several limitations associated with the
current iPSC technology that at present severely restrict any
therapeutic prospects of available iPSC lines [26].
In this report, we describe the generation of equine plu-
ripotent stem cell lines from nonfetal sources by repro-
gramming of fibroblasts obtained from a newborn foal and
from a 2-year-old horse using retroviruses coding for mouse
Oct4, Sox2, c-Myc, and Klf4 sequences. We show that the
reprogrammed cells express several markers of pluripotent
cells, including novel ones in equine, and can differentiate
into derivatives of the 3 germ layers both in vitro and in vivo.
Materials and Methods
Cell culture
Fibroblast cultures were separately derived from skin
samples collected from a newborn male foal and from a 2-
year-old gelding at the equine hospital of the School of Ve-
terinary Studies, University of Edinburgh. Fibroblasts were
grown and expanded from skin explants in Dulbecco’s mod-
ified Eagle medium (DMEM) (Sigma-Aldrich, Irvine, United
Kingdom) containing 10% fetal bovine serum (FBS) gold
(PAA Laboratories Ltd., Yeovil, United Kingdom), 2mM l-
glutamine (Invitrogen, Paisley, United Kingdom), 0.1mM
minimum essential medium (MEM) nonessential amino acids
(Invitrogen), and 1% penicillin–streptomycin (Invitrogen) at
37C in 5% CO2. Once cells reached 90% confluence, they
were passaged using TrypLETM (Invitrogen). For reprogram-
ming experiments, fibroblasts at passage < 7 were used.
Putative iPSCs were grown on mitotically inactivated SNL
feeder cells (CBA-316; Cell Biolabs, San Diego, CA) on 6-well
plates coated with 0.1% gelatin (Sigma-Aldrich) using a
medium containing either the DMEM (Invitrogen) with 20%
fetal calf serum or a knockout DMEM (Invitrogen) supple-
mented with 20% knockout serum replacement (Invitrogen).
Medium preparations also contained 2mM l-glutamine,
0.1mM b-mercaptoethanol (Invitrogen), 0.1mM MEM non-
essential amino acids and 1% penicillin–streptomycin, and
were supplemented with 8 ng/mL human basic fibroblast
growth factor (bFGF) (Peprotech, London, United Kingdom)
and/or 1,000U/mL human leukemia inhibitory factor (LIF)
(Millipore, Watford, United Kingdom). Cells were kept at
37C in 5% CO2. The medium was changed every other day,
and the cells were passaged every 3 days using AccutaseTM
(Sigma-Aldrich).
SNL feeder cells [27] were maintained in the DMEM con-
taining 10% FBS gold, 2mM l-glutamine, 0.1mM MEM non-
essential amino acids, and 1% penicillin–streptomycin. These
cells were mitotically inactivated by incubation with mitomy-
cin C (10mg/mL; Sigma-Aldrich) for 2 h, followed by dissoci-
ation with TrypLE and incubation for at least 1 day in iPSC
medium described above before seeding of putative iPSCs.
Viral constructs and cell reprogramming
Mouse cDNA sequences for Oct4, Sox2, Klf4, and c-Myc
that had been cloned into a Moloney Murine Leukemia
Virus backbone (pMXs) [28] were obtained from Addgene
(Cambridge, MA). Viral particles were produced by indi-
vidually transfecting each of these constructs with the ret-
roviral packaging vector, pCL-10A1 (Imgenex; Cambridge
Bioscience, Cambridge, United Kingdom) using FuGENE
(Roche, West Sussex, United Kingdom) in human embryonic
kidney (HEK) cells (American Type Culture Collection,
Manassas, VA). In addition, the AcGFP1 sequence was ex-
cised from a pAcGFP1-C1 vector (Clontech, Mountain View,
CA) and amplified before being inserted in the retroviral
packaging vector pCLXSN (Imgenex).
Two days after transfection of HEK cells, supernatants
containing concentrates of each of the viral particles encod-
ing for the reprogramming factors were collected, mixed,
filtered, and added to equine fibroblasts that had been
seeded 1 day earlier on gelatin-coated 6-well plates
(1.3 · 105cells/well). To assess transduction efficiency, some
fibroblasts were transduced with the pCLXSN-GFP vector
only. In all cases, the transduction procedure was repeated 1
day later, as described [11]. Cells were passaged onto a
feeder layer in 10-cm dishes (5 · 104 cells/dish) the following
day and transferred to iPSC medium 2 days later. Beginning
2 weeks after transduction, appearing colonies were
mechanically passaged to 96-well plates and individually
expanded by further passaging. Three different reprogram-
ming experiments were performed, and colonies with similar
characteristics were obtained in all cases.
Polymerase chain reaction analyses
Endogenous expression of pluripotency genes in repro-
grammed cells was determined by reverse transcription-
polymerase chain reaction (RT-PCR) using primers specifically
recognizing equine sequences (Table 1). Genomic integration
and expression of the viral transgenes were assessed by PCR
on gDNA and cDNA, respectively, using primers specific for
each of the mouse transcription factors and a primer com-
plementary to a common flanking sequence in the viral
backbone (Table 1). Genomic DNA and total RNA were
extracted with a DNeasy Blood and Tissue Kit (Qiagen,
Crawley, United Kingdom) and an RNeasy mini kit
(Qiagen), respectively. RNA was reverse-transcribed using
Superscript III (Invitrogen) as per the manufacturer’s in-
structions, and PCR was performed with BIOTAQTM DNA
polymerase (Bioline, London, United Kingdom) using an
annealing temperature of 60C–65C and 40 cycles. PCR
products were resolved in 3% agarose gels stained with Sybr
Safe (Invitrogen) and visualized with the Kodak Gel Logic
200 imaging system.
Southern blotting
Ten micrograms of genomic DNA were digested over-
night with BamHI and then electrophoresed in a 0.8% aga-
rose/Tris-Acetate-EDTA gel and transferred to a Hybond-N
membrane (GE Healthcare, Little Chalfont, United King-
dom). This was then hybridized overnight at 65C with
probes isolated from pMXs-Oct4 and pMXs-Klf4 constructs
and labeled using a High Prime DNA labeling kit (Roche)
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and 32P dCTP (Perkin Elmer, Cambridge, United Kingdom).
After washing, membranes were exposed to a phosphor
screen for 3 days and visualized using a Typhoon phos-
phorimage (GE Healthcare). Before rehybridization, mem-
branes were stripped using boiling 0.1% sodium dodecyl
sulfate.
Karyotyping
Cells were synchronized by incubation with thymidine
(10mg/mL; Sigma-Aldrich) for 15 h. After washings with the
DMEM containing 10% FBS, cells were incubated for a fur-
ther 5 h, followed by a second synchronization with thymi-
dine. After washing, cells were incubated with colcemid
(10 mg/mL; Invitrogen) for 2.5 h, and the supernatant was
aspirated, and cells were washed with phosphate-buffered
saline (PBS) before being harvested using TrypLE. After
centrifugation at 1,200 rpm for 8min, the cell pellet was in-
cubated with 0.56% KCl for 8min at room temperature, and
an ice-cold fixative mixture (acetic acid and methanol 1:3)
was added. Centrifugation followed by addition of ice-cold
fixative was repeated 2 more times. Finally, 10–20 mL of
suspension was smeared onto a slide, allowed to dry over-
night at 37C, stained with a Giemsa solution for 15min, and
washed in PBS before mounting a coverslip.
Alkaline phosphatase staining
Alkaline phosphatase activity was determined in repro-
grammed cells using a commercial kit (86R; Sigma-Aldrich)
following the manufacturer’s instructions.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde for 15min at
room temperature and then permeabilized in a 0.5% Triton–
PBS solution, followed by blocking for 50min in PBS con-
taining 2% bovine serum albumin, 0.05% Tween20, and
0.05% Triton. Primary antibody was then incubated over-
night at 4C. The next day, after 3 washes in PBS, 1-h incu-
bation with secondary antibody (Alexa Fluor 568 or 488;
Invitrogen) was performed at room temperature. Cells were
then washed in PBS, and a mounting solution containing
4¢,6-diamidino-2-phenylindole (Sigma-Aldrich) was added
before sealing with a coverslip. Specific antibodies and di-
lutions used are indicated in Table 2. The slides were ob-
served on an Axiovert 25 inverted microscope and a Nikon
EC1 confocal microscope using the 20 · , 40 · , and 63 ·
lenses. The images obtained were processed with ImageJ
software version 1.42q (http://rsb.info.nih.gov/ij).
Induction of cell differentiation in vitro
Putative equine iPSCs were harvested, passaged in a
bacterial culture dish, and allowed to grow in suspension for
Table 1. List of Primers Used for Polymerase Chain Reaction Analyses
Primer Sequence Product (bp)
OCT4 (For) ATTGAGACCCGAGTGAGAGG 74
OCT4 (Rev) CTGATCTGCTGCAGTGTGG
SOX2 (For)a CACCCACAGCAAATGACAGC 252
SOX2 (Rev)a TTTCTGCAAAGCTCCTACCG
NANOG (For)b TCCTCAATGACAGATTTCAGAGA 323
NANOG (Rev)b GAGCACCAGGTCTGACTGTT
DNMT3b (For) CTTCTGCGTGGAGTGTCTGG 169
DNMT3b (Rev) GGTGTCGCTGGTAAAGAAGG
LIN28 (For) CATGGGCTCTGTGTCAAACC 167
LIN28 (Rev) CGGTCATGGACAGGAAGC
REX1 (For) GACGGGAAAGGCCTGGATAGAAG 297
REX1 (Rev) GGCGGTAAGAAGCTGTTGAGAAAGG
GAPDH (For) CATCATCCCTGCTTCTACTGG 117
GAPDH (Rev) TCCACGACTGACACGTTAGG
Viral Common (For) GGATCCCAGTGTGGTGGTACG
Viral Oct4 (Rev) CTGTAGGGAGGGCTTCGGGCACTT 850
Viral Sox2 (Rev) TCACATGTGCGACAGGGGCAG 1,000
Viral Klf4 (Rev) TTAGGCTGTTCTTTTCCGGGGCCACGA 1,200
Viral c-Myc (Rev) TTATGCACCAGAGTTTCGAAGCTGTTC 1,400
aFrom Sumer et al. [24].
bFrom Nagy et al. [23].
Table 2. List of Antibodies Used
for Immunocytochemistry
Marker Supplier Product no. Dilution
Oct4 Santa Cruz Sc-5279 1/300
Sox2 Santa Cruz Sc-17320 1/200
SSEA1 DSHB MC480 1/100
SSEA4 Abcam ab16287 1/300
Nanog Abcam ab80892 1/200
Lin28 Abcam ab63740 1/200
TRA1-60 Cell Signalling 9656 1/200
Rex 1 Millipore MAB4316 1/200
TUJ-1 R&D Systems MAB1195 1/100
AFP R&D Systems MAB1368 1/200
Troponin I Abcam ab19615 1/100
Vimentin Abcam ab8978 1/300
Pan-cytokeratin Sigma C5992 1/200
Nestin Millipore 07-449 1/100
GATA4 Abcam ab5694 1/300
ASMA Abcam ab56944 1/100
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7 days in the DMEM containing 10% FBS. The resulting
embryoid bodies (EBs) were then transferred onto gelatin-
coated 6-well plates in the same medium and allowed to
differentiate for 3 weeks, after which they were fixed before
immunostaining.
Induction of cell differentiation in vivo
Putative equine iPSCs were harvested with TrypLE, and
5· 106 cells resuspended in 100mL of the DMEM medium
containing 10mM HEPES, 10% FBS, and 200nM l-glutamine.
Fifteen microliters of the resulting cell slurry was surgically
grafted under the kidney capsule of NOD/SCID mice. Ani-
mals were euthanized between 5 and 8 weeks after injection,
and tumors recovered and processed for histological analysis.
All animal procedures were carried out under the United
Kingdom Home Office Animals (Scientific Procedures) Act
1986, after approval by the Ethics Review Committee, Uni-
versity of Edinburgh (Project License no. 60/3715).
Results
Reprogramming of equine fibroblasts
We initially reprogrammed fibroblasts derived from a
newborn foal. Chronological events during cell reprogram-
ming are schematically shown in Fig. 1A. Over 75% of fi-
broblasts transduced with control virus showed clear
expression of green fluorescence protein (Fig. 1B), indicating
that the viral vectors used were able to induce efficient
transgene expression in these cells. Nine days after trans-
duction with the 4 transcription factor-coding viruses, the
first iPSC-like colonies distinctly appeared in the culture
dishes (Fig. 1C). These consisted of tight, dome-shaped cell
aggregates with well-defined borders, somewhat resembling
naı¨ve-type pluripotent stem cell colonies generated from
rodents [10,13] and also reported from sheep [22] (Fig. 1D).
This was followed by new colonies appearing periodically
over the next 4 weeks. Beginning on day 18 after transduc-
tion, colonies were individually selected on the basis of their
ESC-like morphology, picked, dissociated, and transferred
onto feeder layers in 96-well plates. New colonies continued
to be collected until day 40, and were in all cases expanded
by sequential passaging onto fresh feeder layers. When ex-
panded in a medium supplemented with FBS and LIF, pu-
tative equine iPSC colonies acquired a relatively loose,
granulated appearance after a few passages, with abundant
detaching cells visible at the edges, suggestive of differenti-
ation. In contrast, after being transferred onto a serum-free
medium supplemented with both bFGF and LIF, colonies
maintained their iPS-like appearance, characterized by tight
colonies with defined edges, a high nucleus-to-cytoplasm
ratio, and prominent nucleoli (Fig. 1E, F).
A total of 103 colonies were initially picked, and 27 of
those were expanded. Twelve colonies could be maintained
FIG. 1. Reprogramming of
equine fibroblasts. (A)
Chronological outline of
equine fibroblast reprogram-
ming. (B) Photomicrograph of
parental fibroblasts after
transduction with pCLXSN-
GFP. (C) Early cell colonies
appearing the second week
after transduction of parental
fibroblasts. (D) Close-up of
colonies in (C). (E) Typical
morphology of an established
iPSC line (line H, passage 14).
(F) Close-up of a colony from
the same cell line. (G) Equine
iPSCs (passage 6) stained for
alkaline phosphatase. (H)
Metaphasic spread of equine
iPSCs (line H) stained with
Giemsa showing a normal
chromosomal complement of
64. White scale bar = 100 mm;
black scale bar= 20 mm. iPSCs,
induced pluripotent stem
cells. Color images available
online at www.liebertpub
.com/scd
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for up to at least 6 passages and all showed alkaline phos-
phatase staining (Fig. 1G). Results from characterization of 4
of these cell lines (H, U, E, B) are shown below. These 4 lines
have now been robustly expanded (over 30 passages in the
case of lines H and U), and they display a typical equine
karyotype (Fig. 1H).
Expression of pluripotency markers
by reprogrammed cells
Immunofluorescence and RT-PCR analyses of the 4 puta-
tive iPSC lines generated from foal fibroblasts revealed ex-
pression of the endogenous pluripotency markers, OCT4,
SOX2, NANOG, and REX1, with 2 of the lines also showing
detectable expression of LIN28 (Figs. 2 and 3A). Ad-
ditionally, all lines showed transcriptional activation of
DNMT3B (Fig. 3A), although this could not be confirmed at
the protein level, as a suitable antibody was not available.
Immunofluorescence analyses also revealed the presence of
the pluripotency-associated cell surface antigens, TRA1-60,
SSEA1, and SSEA4, in the cell lines (Fig. 2). The parental
equine fibroblasts did not show immunostaining for any of
these markers (Supplementary Fig. S1A–H; Supplementary
Data are available online at www.liebertpub.com/scd),
whereas mouse ESCs stained positively for all the markers
analyzed, except TRA-1-60 and SSEA-4 (Supplementary Fig.
S2, left and middle panels), consistent with previous reports
[29]. PCR was also used to determine the expression of the
virus-encoded factors in the established cell lines (Fig. 3B).
As expected, the 4 transgenes were expressed in equine fi-
broblasts 3 days after transduction with viruses. In addition,
all 4 putative iPSC lines showed persistent expression of
Oct4, whereas 2 of the lines also displayed detectable levels
of c-Myc. Despite variable expression of the transgenes in the
reprogrammed cell lines, further analyses revealed effective
genomic integration of the 4 viral sequences in all lines (Fig.
3C). Southern blot analyses showed the same viral integra-
tion pattern in 3 of the 4 lines examined (H, U, and B), in-
dicating that these lines had originally derived clonally from
the same integration event, whereas line E originated from a
different event (data not shown). Nonetheless, taken to-
gether, the results of expression analyses indicate effective
transcriptional activation of the endogenous pluripotency
machinery in the reprogrammed equine cells.
In vitro differentiation potential
of reprogrammed cells
The capacity of putative iPSCs generated from foal fibro-
blasts to undergo differentiation in vitro was investigated by
placing the cells on a nonadherent Petri dish with FBS in the
absence of growth factors. Under such conditions, these cells
were able to readily form EBs (Fig. 4A), which were then
seeded on gelatin-coated plates to allow differentiation.
FIG. 2. Pluripotency marker
immunostaining of repro-
grammed cell lines. Re-
presentative images showing
immunostaining of equine
iPSCs (line H) for (A) OCT4,
(B) SOX2 (C) NANOG, (D)
REX1, (E) LIN28, (F) TRA1-
60, (G) SSEA1, and (H)
SSEA4. Secondary antibody
was conjugated to Alexa
Fluor 568 (red) or Alexa Fluor
488 (green), and DAPI was
used for nuclear counter-
staining (blue). The second and
fourth columns of the panel
display the merged images
for Alexa Fluor and DAPI.
Scale bar = 50mm. DAPI, 4¢,
6-diamidino-2-phenylindole.
Color images available online
at www.liebertpub.com/scd
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Outgrowths of heterogeneous populations of differentiating
cells began to appear soon after, and 28 days after plating,
the differentiated cells were immunostained. Different pop-
ulations of cells were identified that expressed markers of
ectoderm (Fig. 4B–D), mesoderm (Fig. 4E, F), or endoderm
(Fig. 4G, H). Adult equine tissues were also stained as pos-
itive controls for the different differentiation markers ana-
lyzed (Supplementary Fig. S3).
Ability of equine iPSCs to undergo multilineage
differentiation in vivo
To determine whether putative equine iPSCs displayed
in vivo pluripotency, line H (passage 17) was injected into
the kidney capsule of 3 SCID mice. All injected mice devel-
oped tumors, which appeared as large globular solid masses
about 2 cm in diameter at 5–8 weeks after injection (Fig. 5A).
These tumors showed discrete areas of necrosis, which may
have resulted from their relatively high growth rate. Further,
all tumors showed clear evidence of differentiation into de-
rivatives of the 3 germ layers (Fig. 5B–D), including kerati-
nized epithelium (ectoderm), bone (mesoderm), and gut-like
epithelium (endoderm).
Reprogramming of fibroblasts from an adult horse
Finally, since the eventual application of iPSC technology
in equine regenerative medicine would most often involve
derivation of iPSCs from young performance horses rather
than neonates, we aimed to determine whether fibroblasts
obtained from a 2-year-old gelding could also be repro-
grammed to pluripotency. Reprogrammed colonies were
obtained that were morphologically similar to iPSCs derived
from foal fibroblasts. Six different colonies were picked and
gave rise to different putative clonal populations. One of the
resulting cell lines (Fig. 6A) was further analyzed for the
expression of selected pluripotency markers, namely ALP,
OCT4, SOX2, LIN28, and TRA-1-60, and for its ability to
differentiate into derivatives of the 3 germ layers. The pu-
tative adult derived iPSCs stained positively for the above
pluripotency markers (Fig. 6B–F), consistent with results
with iPSCs derived from foal fibroblasts. Further, they
readily formed EBs in vitro (Fig. 6G) that were able to
give rise to cells expressing markers of ectoderm (TUJ-1),
mesoderm (alpha-smooth muscle actin), and endoderm
(alpha-fetoprotein) (Fig. 6H–J), demonstrating their capacity
to differentiate into multiple cell lineages.
Discussion
In this report, we describe the establishment of stable
equine iPSC lines using the 4-transcription factor technique,
initially described by Takahashi and Yamanaka [10]. Unlike
previous reports, we used nonfetal cell sources to generate
equine pluripotent cell lines. Embryonic stem-like cells have
been derived from horse blastocysts [8,9], whereas in a recent
study, equine iPSCs were obtained from retrotransposon-
mediated reprogramming of fibroblasts taken from 55-
day-old conceptuses, which correspond to a very early stage
during the 11-month long period of prenatal development
in the horse [23]. In other species, iPSCs were also generated,
at least initially, using fetal fibroblasts, as they represent
a relatively undifferentiated cell type compared to later
FIG. 3. PCR analysis of reprogrammed cell lines. (A)
Messenger RNA levels of equine-specific pluripotency gene
sequences in equine testis (positive control) and in repro-
grammed cell lines (H, U, E, and B). In all cases, non-
transduced equine fibroblasts (EqF) were used as negative
controls, and a no-RT control (-RT) was also included.
GAPDH was used as loading control. (B) Messenger RNA
levels of viral transgenes determined by RT-PCR in equine
fibroblasts 3 days after transduction with retroviruses
(Transd EqF) and in reprogrammed cell lines. (C) Genomic
DNA levels of viral transgenes determined by PCR in equine
fibroblasts 3 days after transduction and in reprogrammed
cell lines. A no-template control (C) was included. RT-PCR,
RT-polymerase chain reaction.
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developmental stages, and therefore they are, in principle,
more readily reprogrammable [10,14,15,21]. Consistent with
this, it has been shown that, relative to adult mesenchymal
cells, equine fetal fibroblasts express high levels of key re-
programming factors [30] that very likely facilitate the re-
programming of these cells. In contrast, in the present study,
we could not detect expression of any of the pluripotency
factors analyzed in parental fibroblasts, either by immuno-
cytochemistry or by PCR, consistent with their postfetal or-
igin. The present results represent a step forward toward the
generation and biomedical application of reprogrammed
cells from clinical equine patients.
The equine cell lines generated in this study showed nu-
merous features associated with pluripotency. These include
transcriptional reactivation of endogenous OCT4 and ex-
pression of 3 different cell surface antigens, all of which have
been reported in the inner cell mass of equine blastocysts [31]
as well as in equine ESC-like cells [8,9,32] and iPSCs [23].
Equine iPSCs in the present report also expressed NANOG,
in agreement with the earlier iPSC report by Nagy et al. [23],
as well as other ESC-associated factors, namely SOX2, REX1,
LIN28, and DNMT3B, which are transcriptionally activated
during reprogramming of human, mouse, and pig cells
[10,15,33], but have not been previously reported in equine
pluripotent cells. The reactivation of endogenous pluri-
potency markers is well known to be associated with late
stages of reprogramming [34]. Furthermore, Chan et al. [35]
demonstrated that 3 of the markers found in our equine
iPSCs, namely TRA-1-60, REX1, and DNMT3B, were bona fide
indicators of fully reprogrammed human iPSCs, a conclusion
that is consistent with the ability of the equine iPSCs re-
ported in the present study to readily produce differentiated
teratomas upon injection into SCID mice. In a previous study
[23], equine cells reportedly resembling primed-type PSCs
were generated using an inducible transposon-based ex-
pression system and culture conditions that included LIF and
bFGF as well as a combination of different signaling path-
way inhibitors that are reportedly necessary to generate na-
ı¨ve-type PSCs [36]. In the present study, stable equine
pluripotent cell lines could be generated and maintained
FIG. 4. In vitro differentia-
tion potential of repro-
grammed cell lines. (A)
Embryoid bodies forming 5
days after equine iPSCs (line
H, passage 12) were placed in
suspension culture. (B–H)
Immunostaining of differenti-
ated cells for markers of ec-
toderm (B–D), mesoderm (E,
F), or endoderm (G, H). Sec-
ondary antibody was conju-
gated to Alexa Fluor 568 (red)
or Alexa Fluor 488 (green),
and DAPI was used for nu-
clear counterstaining (blue).
The second and fourth columns
of the panel display the
merged images for Alexa
Fluor and DAPI. Scale bar =
20 mm. Color images avail-
able online at www.liebert
pub.com/scd
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without the need to use signaling inhibitors. Compared with
the cells reported by Nagy et al. [23], in general, our cell lines
did not display obvious morphological features of typical
primed-type PSCs, but they predominantly grew as rela-
tively tight, dome-like shaped cell aggregates, which is more
typical of naı¨ve-type PSCs. These apparent differences in the
cells obtained between the 2 studies may have been derived
from differences in the conditions used to generate and
maintain the reprogrammed cells and/or from differences in
the criteria used to select ESC-like colonies for expansion.
Similar discrepancies in the morphology of iPSCs from the
same species have been reported for sheep and pig
[21,22,37,38], and they could be attributed to the use of hu-
man ESC versus mouse ESC culture conditions in some
studies [38], but not in others [21,22]. Clearly, greater un-
derstanding of the molecular pathways involved in plur-
ipotency in these species, as well as of the different
pluripotent states that may be potentially generated in vitro
[38], is required to reconcile these discrepancies.
The MMLV vector used for reprogramming in this study
was similar to the one used to generate the first mouse and
human iPSC lines [10,11]. Because, in principle, such vectors
become transcriptionally repressed during the late stages of
reprogramming [10,11], in some studies, stable iPSC lines
could not be generated using MMLV vectors, but the use of
lentiviral vectors, which may not undergo the same levels of
transcriptional repression, was required [13]. Further, many
successful attempts to derive iPSC lines from domestic spe-
cies, including horse, have involved the use of lentiviral or
other expression vectors under transcriptional control by an
inducible promoter, which ensures sustained transgene ex-
pression required to achieve and maintain the pluripotent
state [14,15,20,23]. The equine iPSCs reported in the present
study showed partial silencing of transgenes characterized
by sustained expression of Oct4 in all the lines examined and
expression of c-Myc in some of the lines. This pattern is
consistent with that reported in sheep iPSCs produced using
the same vectors [22]. In addition, studies using a similar
retroviral expression system in other species often reported
silencing of one or several of the transgenes in the iPSC lines
generated, except for Oct4, whose expression was usually
maintained in all or most of the lines [13,33,39,40]. These
findings suggest that clonal populations that fail to silence
viral Oct4 may be distinctly selected for during reprogram-
ming. In that context, the ectopic Oct4 may critically con-
tribute, together with the reactivated endogenous
pluripotency genes, to the attainment and maintenance of the
induced pluripotent state. So far, all iPSC lines reported from
domestic species have shown to be dependent on continuous
transgene expression for long-term propagation, as demon-
strated with the use of inducible reprogramming vectors
[14,20,21,41,42]. Similarly, equine iPSCs described in an
earlier study quickly underwent differentiation after the ex-
pression of reprogramming genes from a transposon-based
vector was turned off [23]. Significant risks associated with
insertional mutagenesis and incomplete transgene silencing
severely restrict the clinical potential of iPSCs generated with
current virus-based technology, a limitation that will only be
overcome once robust iPSC lines can be efficiently generated
using integration-free or nongenetic approaches [34]. An in-
teresting observation in the present study was that 3 of the
foal-derived iPSC lines characterized (H, U, and B) appeared
FIG. 5. In vivo differentiation potential of reprogrammed
cell lines. (A) Tumor resulting from injection of equine iPSCs
into SCID mice is pictured. The tumor can be seen (white
arrow) growing adjacent to the kidney (identified by a black
arrow). Tumors obtained contained differentiated derivatives
of the 3 germ layers (stained with hematoxylin and eosin),
including keratinized epithelium (B), bone (C), and gut-like
epithelium (D) structures (identified in each photo by black
arrows). Color images available online at www.liebertpub
.com/scd
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to be clonally derived from the same integration event, yet
these 3 lines were not phenotypically identical as showed by
differences in the expression of pluripotency genes (LIN28)
and viral c-Myc (Fig. 3); since the 3 lines were expanded
using the same culture conditions, the observed differences
likely reflect the stochastic nature of iPSCs derivation.
In the study by Nagy et al. [23], a lack of suitable anti-
bodies prevented the authors from assessing the in vitro
pluripotency of the reported equine iPSCs. In the present
study, we used a panel of antibodies for various differenti-
ation markers, which we validated in adult equine tissues
(Supplementary Fig. S3), to demonstrate the capacity of re-
programmed equine cells to undergo differentiation into
derivatives of the 3 germ layers in vitro. The pluripotency of
putative equine iPSCs in vivo was demonstrated by injecting
these cells into the kidney capsule of SCID mice, a route that
is technically more demanding than subcutaneous or intra-
muscular injection, but that facilitates discrimination be-
tween the resulting tumor and host tissues. In previous
studies, equine ESC-like cells failed to produce tumors
when injected into the testes of SCID mice [9] whereas
subcutaneous injection of putative equine iPSCs resulted in
growth of tumors after 4 months and only after injected
mice had been temporarily fed with doxycycline to main-
tain expression of the reprogramming transgenes, a strategy
that was reportedly necessary to avoid premature cell dif-
ferentiation in vivo [23]. Equine iPSCs in the present study
were able to spontaneously maintain their pluripotency
in vivo and generated tumors that grew over a period, 5–8
weeks, which was intermediate between periods normally
reported for teratomas derived from mouse and human
iPSCs [10,11]. Outgrowths resulting from the injected cell
line in our study were confirmed to be teratomas, as
they contained differentiated derivatives of the 3 germ
layers, constituting to this date the most stringent proof of
pluripotency for equine iPSCs.
Finally, we also showed that adult equine fibroblasts can
be reprogrammed to generate cell lines that are morpho-
logically similar to iPSCs produced from neonatal fibro-
blasts, express similar pluripotency factors, and readily
differentiate into derivatives of the 3 germ layers in vitro.
The age of the donor animal in this experiment, 2 years,
corresponds to the career peak of most racing horses, pro-
viding support to the prospect of using iPSCs for equine
regenerative medicine in the future.
The potential of pluripotent stem cells in veterinary
medicine, and particularly in equine health, is similar to that
in human medicine. Although significant technical advances
still need to be made to eliminate constraints associated with
genetic, epigenetic, and immunogenic aspects of iPSCs that
at the moment severely restrict their clinical potential [43],
huge progress has already been made in the application of
iPSC technology for in vitro modeling of diseases and ther-
apeutics [26]. In that regard, there are a number of equine
diseases that would be amenable to experimental modeling
using iPSCs. Further, horses could be used as preclinical
models for human stem cell-based therapies [1]. Our results
provide an important step toward that goal by demonstrat-
ing that nonfetal equine somatic cells can be reprogrammed
to cells that are pluripotent both in vitro and in vivo. These
established cell lines should facilitate the realization of the
veterinary potential of the iPSC technology.
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